Kentucky Retirement Systems Purchases 178,402 Shares of Pfizer Inc. $PFE

Posted by Francis Steltz on Jul 30th, 2026

Kentucky Retirement Systems boosted its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 50.0% in the 1st quarter, Holdings Channel.com reports. The fund owned 535,087 shares of the biopharmaceutical company’s stock after purchasing an additional 178,402 shares during the period. Kentucky Retirement Systems’ holdings in Pfizer were worth $16,390,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of PFE. Bull Harbor Capital LLC purchased a new stake in Pfizer in the 1st quarter worth approximately $464,000. Strategic Investment Advisors MI grew its position in shares of Pfizer by 22.0% during the 1st quarter. Strategic Investment Advisors MI now owns 49,294 shares of the biopharmaceutical company’s stock valued at $1,384,000 after purchasing an additional 8,896 shares in the last quarter. Ashton Thomas Securities LLC bought a new position in shares of Pfizer in the first quarter worth $229,000. Arkadios Wealth Advisors raised its position in shares of Pfizer by 5.2% in the first quarter. Arkadios Wealth Advisors now owns 410,747 shares of the biopharmaceutical company’s stock worth $11,534,000 after buying an additional 20,477 shares in the last quarter. Finally, IFS Group LLC purchased a new stake in shares of Pfizer in the first quarter worth $356,000. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Citigroup boosted their target price on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Bank of America dropped their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective for the company in a report on Tuesday, June 9th. HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Finally, Guggenheim dropped their target price on shares of Pfizer from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $28.50.

View Our Latest Stock Analysis on Pfizer

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: The European Commission granted marketing authorization for Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine for the 2026–2027 season. The approval supports continued seasonal vaccine revenue, although demand remains difficult to forecast. BioNTech and Pfizer Secure EU Approval for XFG-Adapted COVID-19 Vaccine for 2026-2027 Season
Positive Sentiment: Québec selected Pfizer’s PREVNAR 20 for its publicly funded pediatric pneumococcal immunization program. The decision could expand vaccine adoption and provide recurring sales support in the Canadian market. Pfizer’s PREVNAR 20 Selected for Québec’s Publicly Funded Pediatric Pneumococcal Immunization Program
Positive Sentiment: Erste Group Bank raised its fiscal 2027 Pfizer earnings estimate to $2.86 per share from $2.84. The increase, though modest, signals slightly improved confidence in the company’s future earnings trajectory. Pfizer FY2027 Earnings Estimate Update
Neutral Sentiment: Pfizer completed a Phase 1 study evaluating formulation and dosing for ibuzatrelvir, an oral antiviral candidate. The update advances development but offers no evidence yet of efficacy or commercial approval. Pfizer Fine Tunes Ibuzatrelvir Tablet in Completed Phase 1 Study
Neutral Sentiment: Analysts expect Pfizer to potentially beat second-quarter earnings estimates, supported by key products and cost or operational improvements. Investors are focused on whether management maintains its full-year 2026 earnings guidance of $2.80–$3.00 per share and addresses COVID-related revenue declines. Pfizer Expected to Beat Earnings Estimates
Negative Sentiment: Investors remain cautious ahead of the earnings release because Pfizer must offset declining COVID-related sales and demonstrate progress in cancer, obesity and other growth areas. Uncertainty around guidance and the pace of its business reset may be limiting buying interest.

Pfizer Trading Down 0.4%

Shares of PFE stock opened at $25.16 on Thursday. The business has a 50-day moving average price of $25.08 and a two-hundred day moving average price of $26.16. Pfizer Inc. has a 12-month low of $23.11 and a 12-month high of $28.75. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The firm has a market cap of $143.40 billion, a P/E ratio of 19.21 and a beta of 0.35.

Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company’s revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

About Pfizer

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.